文献速递冠心病血脂与心血管预防

择期血运重建联合药物治疗与单纯药物治疗对稳定性冠心病患者心源性死亡影响的系统评价与荟萃分析

Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis.
PubMed 文献 · Eur Heart J · 2021-01-01

结果显示血运重建组心源性死亡风险降低(RR 0.79,95%CI 0.67-0.93,P<0.01),自发性心肌梗死风险降低(RR 0.74,95%CI 0.64-0.86,P<0.01),但全因死亡、任何心肌梗死及卒中风险无显著差异。

要点

  • 稳定性冠心病患者择期血运重建联合药物治疗较单纯药物治疗降低心源性死亡风险。
  • 血运重建降低自发性心肌梗死风险,心源性生存获益随随访时间延长而改善。
  • 全因死亡、任何心肌梗死及卒中风险两组间无显著差异。

核心结论

  • 稳定性冠心病患者中,择期血运重建联合药物治疗较单纯药物治疗降低心源性死亡率。
  • 血运重建后的心源性生存获益随随访时间延长而改善,并与自发性心肌梗死减少相关。

研究设计与样本

  • 系统评价与荟萃分析,检索MEDLINE、EMBASE、Google Scholar等数据库自建库至2020年11月。
  • 主要终点为心源性死亡,采用随机效应模型计算率比(RR)及95%置信区间。

主要发现

  • 与单纯药物治疗相比,血运重建组心源性死亡风险降低(RR 0.79,95%CI 0.67-0.93,P<0.01)。
  • 血运重建组自发性心肌梗死风险降低(RR 0.74,95%CI 0.64-0.86,P<0.01)。
  • 全因死亡风险两组无显著差异(RR 0.94,95%CI 0.87-1.01,P=0.11)。
  • 任何心肌梗死(P=0.14)及卒中风险(P=0.30)两组无显著差异。
  • 荟萃回归显示心源性死亡风险降低与随访时间呈线性相关(每4年随访RR 0.81,95%CI 0.69-0.96,P=0.008),并与自发性心肌梗死绝对差(P=0.01)及基线多支病变百分比(P=0.004)相关。

临床怎么用

  • 对于稳定性冠心病患者,在药物治疗基础上考虑择期血运重建可能降低心源性死亡风险。
  • 血运重建的心源性生存获益在随访时间较长及多支病变患者中可能更明显。

局限性

  • 原文未报告纳入试验的具体特征及异质性评估细节。
  • 原文未报告出血、手术并发症等安全性终点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The value of elective coronary revascularisation plus medical therapy over medical therapy alone in managing stable patients with coronary artery disease is debated. We reviewed all trials comparing the two strategies in this population. METHODS AND RESULTS: From inception through November 2020, MEDLINE, EMBASE, Google Scholar, and other databases were searched for randomised trials comparing revascularisation against medical therapy alone in clinically stable coronary artery disease patients. Treatment effects were measured by rate ratios (RRs) with 95% confidence intervals, using random-effects models. Cardiac mortality was the pre-specified primary endpoint. Spontaneous myocardial infarction (MI) and its association with cardiac mortality were secondary endpoints. Further endpoints included all-cause mortality, any MI, and stroke. Longest follow-up data were abstracted. The study is registered with PROSPERO (CRD42021225598). Twenty-five trials involving 19 806 patients (10 023 randomised to revascularisation plus medical therapy and 9783 to medical therapy alone) were included. Compared with medical therapy alone, revascularisation yielded a lower risk of cardiac death [RR 0.79 (0.67-0.93), P < 0.01] and spontaneous MI [RR 0.74 (0.64-0.86), P < 0.01]. By meta-regression, the cardiac death risk reduction after revascularisation, compared with medical therapy alone, was linearly associated with follow-up duration [RR per 4-year follow-up: 0.81 (0.69-0.96), P = 0.008], spontaneous MI absolute difference (P = 0.01) and percentage of multivessel disease at baseline (P = 0.004). Trial sequential and sensitivity analyses confirmed the reliability of the cardiac mortality findings. All-cause mortality [0.94 (0.87-1.01), P = 0.11], any MI (P = 0.14), and stroke risk (P = 0.30) did not differ significantly between strategies. CONCLUSION: In stable coronary artery disease patients, randomisation to elective coronary revascularisation plus medical therapy led to reduced cardiac mortality compared with medical therapy alone. The cardiac survival benefit after revascularisation improved with longer follow-up times and was associated with fewer spontaneous MIs.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Navarese EP, Lansky AJ, Kereiakes DJ, et al. Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis. Eur Heart J. 2021. PMID: 34002203. doi:10.1093/eurheartj/ehab246

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。